explore -WSS

explore

author：explore 2025-08-11 11:45:37 - browse：64959

BRENDAN SMIALOWSKI/AFP via Getty Images

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years.

Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its products for thousands of dollars more than it otherwise could. From 2017 to 2020, the company sold nearly 8,000 devices with the non-functioning component.

STAT published new details about the Stimwave story last May, after former employees described how Perryman broke into Stimwave’s Florida headquarters to steal back devices after her termination in 2019. The fraud laid bare the limits of the Food and Drug Administration’s device surveillance system, doctors’ ability to scrutinize device effectiveness, and how impossible it is for patients to get answers about the implants they receive.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Steward Health Care expansion into Malta flopped

hotspot

WSS

Medical devices makers are asking for forgiveness, not permission

Texas board proposes rules on abortion law emergency exemption

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Biotech investment managers search for lucrative opportunities

Antibiotic resistance nearly killed me, so I'm raising awareness of it

knowledge

explore

explore

The high cost of giving birth even with insurance

Readout Newsletter: Illumina, CRISPR, Regeneron

Medicare details structure of new drug price negotiation program

Lab trade group sues FDA to halt regulation of lab

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Guidelines to prevent youth baseball injuries need more muscle

Asbestos ban is immediate, but health effects will linger for decades

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

hotspot

Focused ultrasound for uterine fibroids: an uphill battle

Testing GLP

Cancer, immunology, HIV research ensnared in fetal tissue politics

AI used to predict Covid

Biotech investment managers search for lucrative opportunities

Health insurers say they are turning to AI to cut costs, improve care

focus

focus

hotspot

focus